Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2011
Business Overview: NAI provides private label contract manufacturing services for nutritional supplements and health care products. The company also markets branded products (Pathway to Healing) and generates royalty income from its CarnoSyn beta-alanine patent estate. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2011 | Nine Months Ended Mar 31, 2011 |
|---|---|---|
| Net Sales | $13,375 | $41,484 |
| Gross Profit | $2,384 | $7,908 |
| Gross Margin | 17.8% | 19.1% |
| Operating Income | $258 | $2,307 |
| Net Income | $181 | $1,947 |
| Cash and Cash Equivalents | $11,892 | $11,892 (Ending Balance) |
| Operating Cash Flow (9mo) | N/A | $4,585 |
| Total Debt | $0 | $0 |
| Available Credit Line | $5,000 | $5,000 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 21% for the quarter and 19% for the nine-month period compared to the prior year. This was driven by a 21% drop in private label contract manufacturing sales, primarily due to lower volumes from two major customers (Mannatech and NSA International).
- Profitability Compression: Operating income fell 70% for the quarter and 23% for the nine-month period. Net income dropped 90% for the quarter and 50% for the nine-month period.
- Margin Improvement: Despite revenue declines, gross margin improved to 19.1% for the nine-month period (up from 16.7% prior year) due to a favorable shift in sales mix and reduced overhead expenses.
- Royalty Growth: Royalty income from the CarnoSyn beta-alanine license agreement increased 84% to $1.3 million for the nine-month period, partially offsetting manufacturing sales declines.
- Customer Concentration: Revenue concentration from the two largest customers decreased to 73% of total sales for the nine-month period, down from 83% in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management expects net sales and operating income for the fourth quarter of fiscal 2011 to be lower than the comparable prior year period due to uncertain economic conditions, reduced sales volumes, and increased litigation expenses.
- Litigation Risk: NAI is engaged in patent infringement litigation against Vital Pharmaceutical, Inc. and DNP International Co., Inc. regarding beta-alanine. Litigation expenses were approximately $770,000 for the nine months ended March 31, 2011. Management anticipates expenses of $400,000 to $500,000 per quarter for the remainder of the fiscal year.
- Foreign Exchange: The company faces risks from currency fluctuations, particularly the Euro. NAI utilizes forward contracts to hedge forecasted sales denominated in foreign currencies.
- Strategic Initiatives: The company plans to re-launch portions of its Pathway to Healing branded product line and increase marketing efforts to diversify revenue streams.
Investor Verification Checklist
- Customer Dependency: Verify the stability of relationships with the top two customers, which collectively accounted for 73% of sales in the first nine months of fiscal 2011.
- Litigation Costs: Monitor the trajectory of legal expenses related to the beta-alanine patent lawsuit, which could significantly impact future profitability.
- Branded Product Recovery: Assess the effectiveness of the re-launch strategy for the Pathway to Healing product line, which has seen consistent sales declines.
- Credit Facility Covenants: Confirm continued compliance with the Wells Fargo Credit Agreement covenants, specifically the requirement to maintain net income after taxes of at least $750,000 on a trailing four-quarter basis.
- Foreign Currency Exposure: Review the impact of Euro fluctuations on the European subsidiary (NAIE), which accounts for a significant portion of international sales.